GNAS and pancreatic intraductal papillary-mucinous neoplasm: Our data show that GNAS and KRAS mutations (18.8% and 10.4%) can already be found in the cfDNA of IPMN patients in general, concluding that IPMNs, as preneoplastic disease, can shed mutated KRAS and GNAS cfDNA into the bloodstream.